Header Logo

Connection

James Mulshine to CD5 Antigens

Back to Details
This is a "connection" page, showing publications James Mulshine has written about CD5 Antigens.
James Mulshine
Connection Strength
0.040
CD5 Antigens
  1. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2691-700.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.